HER2-Positive Breast Cancer
Advertisement
Pembrolizumab plus dual HER2 blockade may offer a chemo-free option for early HER2+ breast cancer, phase 2 data suggest.
Enhertu plus THP improved pCR over standard chemo in high-risk HER2+ early breast cancer, DESTINY-Breast11 shows.
Dr. Soliman explores dendritic cell vaccines to boost immunity and cut chemo toxicity in early HER2-positive breast cancer.
Pilot study shows HER2-targeted dendritic cell vaccines may enhance immune response in early HER2-positive breast cancer.
Enhertu plus pertuzumab significantly improved PFS vs. THP in 1L HER2+ mBC, marking the first advance in over a decade.
The CDK4/6 inhibitor showed meaningful improvement in HR+, HER+ disease.
A year of treatment with the antibody-drug conjugate trastuzumab emtansine effectively prevents HER2-positive BC ...
Eribulin is noninferior to trastuzumab and pertuzumab plus taxane in treating HER2-positive breast cancer.
The HER2DX ERBB2 mRNA score was significantly associated with improved survival in patients with metastatic HER2+ BC.
Using the HER2DX genomic tool is feasible in a real-world setting of patients with early-stage HER2-positive breast cancer.
CNS radiotherapy with pyrotinib and capecitabine improves CNS progression in breast cancer patients with brain metastases.
Will HER2CLIMB-02 study data impact the breast cancer landscape?
In a recent study, published in JAMA Oncology, researchers evaluated whether the HER2DX assay could predict ...
Researchers of a study, published in Radiotherapy and Oncology, evaluated the effects of post-mastectomy radiation ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.